Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
1. Verfasser: | Paul, Pulock |
---|---|
Weitere Verfasser: | Azam,Faruque |
Format: | Abschlussarbeit |
Sprache: | English |
Veröffentlicht: |
Brac University
2024
|
Schlagworte: | |
Online Zugang: | http://hdl.handle.net/10361/23954 |
Ähnliche Einträge
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
von: Rahman, Tasnim
Veröffentlicht: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
von: Hoque, Ismoth Ara
Veröffentlicht: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
von: Karim, Samia Binte
Veröffentlicht: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
von: Flora, Sanzida Alam
Veröffentlicht: (2024) -
A review on targeted therapies for lung cancer
von: Ashraf, Anushey
Veröffentlicht: (2023)